Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00036738 · OUTCOME

Overall Survival

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib · Source last updated 2020-01-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Assessed up to 5 years

What was measured

Number of patients surviving up to five years post-transplant.

Groups in this outcome

Treatment (Allogeneic Nonmyeloablative HSCT)

See Detailed Description Cyclosporine: Given IV or PO Dasatinib: Given PO Fludarabine Phosphate: Given IV Imatinib Mesylate: Given PO Mycophenolate Mofetil: Given PO Nilotinib: Given PO Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo nonmyeloablative allogeneic PBSC transplantation Peripheral Blood Stem Cell Transplantation: Undergo allogeneic PBSC transplantation Therapeutic Allogeneic Lymphocytes: Given IV Total-Body Irradiation: Undergo TBI

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Allogeneic Nonmyeloablative HSCT)28

Reported measurements

6 Months
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Allogeneic Nonmyeloablative HSCT)26Not reportedNot reportedNot reportedNot reported
1 Year
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Allogeneic Nonmyeloablative HSCT)24Not reportedNot reportedNot reportedNot reported
2 Years
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Allogeneic Nonmyeloablative HSCT)19Not reportedNot reportedNot reportedNot reported
3 Years
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Allogeneic Nonmyeloablative HSCT)17Not reportedNot reportedNot reportedNot reported
4 Years
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Allogeneic Nonmyeloablative HSCT)16Not reportedNot reportedNot reportedNot reported
5 Years
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Allogeneic Nonmyeloablative HSCT)13Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        26
    title
    6 Months
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        24
    title
    1 Year
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        19
    title
    2 Years
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        17
    title
    3 Years
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        16
    title
    4 Years
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        13
    title
    5 Years
denoms
  1. counts
    1. group Id
      OG000
      value
      28
    units
    Participants
description
Number of patients surviving up to five years post-transplant.
groups
  1. description
    See Detailed Description Cyclosporine: Given IV or PO Dasatinib: Given PO Fludarabine Phosphate: Given IV Imatinib Mesylate: Given PO Mycophenolate Mofetil: Given PO Nilotinib: Given PO Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo nonmyeloablative allogeneic PBSC transplantation Peripheral Blood Stem Cell Transplantation: Undergo allogeneic PBSC transplantation Therapeutic Allogeneic Lymphocytes: Given IV Total-Body Irradiation: Undergo TBI
    id
    OG000
    title
    Treatment (Allogeneic Nonmyeloablative HSCT)
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Assessed up to 5 years
title
Overall Survival
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice